Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Orencia in recently diagnosed Type 1 diabetes
NCT04118153Phase 1Completed
- Start
- Mar 2021
- Primary completion
- May 2024
- Modality
- Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of abatacept in type 1 diabetes mellitus (T1D). Primary endpoints: Change in insulin antibody titers at 2 weeks, Change in frequency of B cells within total PBMC at 2 weeks and 5 more. Started Mar 2021; status: completed.
02
Drugs
abatacept
03
Conditions
type 1 diabetes mellitus (T1D)
Beyond the preview
Go deeper on NCT04118153.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04118153.